Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 288.63% is 295% above its 4-year average of 73.01%, near the high end of its 4-year range (3.76%–288.63%).
As of the fiscal period ended Tuesday, June 30, 2026. 65.02% above its 12-month average of 174.90%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 288.63%.
DEBT TO ASSETS RATIO
288.63%
DEBT TO ASSETS RATIO AVG TTM
174.90%
DEBT TO ASSETS RATIO AVG 3Y
84.62%
DEBT TO ASSETS RATIO AVG 5Y
73.01%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+65.02%
CURRENT VS 3Y AVG
+241.07%
CURRENT VS 5Y AVG
+295.34%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.12%
median of 395 covered companies
CURRENT VS SECTOR MEDIAN
+240423.29%
vs the sector median at left
Akanda Corp.
Market Cap
$61819.00
Debt to Assets Ratio
288.63%
TTM Avg
174.90%
3Y Avg
84.62%
5Y Avg
73.01%
Market Cap
$787624.00
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$878396.00
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$885939.00
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$888387.00
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.02M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.11M
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.36M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Akanda Corp. (AKAN) | $61819.00 | 288.63% | 174.90% | 84.62% | 73.01% |
| CDT Equity Inc. (CDT)vs › | $707297.00 | 0.38% | N/A | N/A | N/A |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $787624.00 | 0.01% | N/A | N/A | N/A |
| Bone Biologics Corporation (BBLG)vs › | $878396.00 | 0.00% | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $885939.00 | 0.01% | N/A | N/A | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $888387.00 | 0.00% | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | 0.00% | N/A | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.11M | 0.11% | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.36M | 0.01% | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.37M | 0.00% | N/A | N/A | N/A |
Debt/Assets
288.6%
Debt/Equity
N/A
Current Ratio
0.22
Interest Coverage
-5.4x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 288.63% |
| 2025-12-31 | 229.78% |
| 2025-06-30 | 6.30% |
| 2024-12-31 | 4.46% |
| 2024-06-30 | 3.76% |
| 2023-12-31 | 45.24% |
| 2023-06-30 | 14.21% |
| 2022-12-31 | 10.00% |
| 2022-06-30 | 8.81% |
| 2021-12-31 | 118.90% |
| 2020-12-31 | 213.41% |
